Docoh
Loading...

HGEN Humanigen

Filed: 28 May 21, 5:00pm

 

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): May 28, 2021

Humanigen, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware 001-35798 77-0557236
(State or other Jurisdiction of
Incorporation)
 (Commission File No.) 

(IRS Employer Identification No.)

 

 

533 Airport Boulevard, Suite 400

Burlingame, CA 94010

(Address of principal executive offices, including zip code)

 

(650) 243-3100

(Registrant’s telephone number, including area code)

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2):

 

 oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

 oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

 oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

 oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each classTrading Symbol(s)Name of each exchange on which registered
Common StockHGENThe Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

 

Emerging growth company o

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

 

 

 

   
 

 

Item 8.01.Other Events.

 

On May 28, 2021, Humanigen, Inc. (the “Company”) issued a press release announcing that it had submitted an application to the US Food and Drug Administration requesting emergency use authorization for lenzilumab for the treatment of patients hospitalized with COVID-19. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

 

Item 9.01.Financial Statements and Exhibits

 

 (d)Exhibits

 

 

Exhibit No.Exhibit Description
  
99.1Press release, dated May 28, 2021

 

   
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

           

 Humanigen, Inc.
  
 By: /s/ Cameron Durrant 
  

Name: Cameron Durrant
Title:   Chairman of the Board and Chief

Executive Officer

 

Dated: May 28, 2021